how does glp 1 lower blood pressure GLP-1 drugs tied to risks in certain patients, study finds. MORE⬇️ glp-1 and hypertension Obesity treatment

This graphic highlights just how system-wide their effects really are The Upside (why everyone is paying attention): Metabolic control Insulin secretion Glucagon Glucose uptake (muscle, adipose) Hepatic glucose production Weight loss drivers Gastric emptying earlier satiety Appetite (central nervous system) Lipolysis & thermogenesis Cardiorenal benefits Cardioprotection Diuresis/natriuresis Improved lipid & fatty acid metabolism Potential neurological benefits Signals around neuroprotection, synaptic function, and motor activity The Tradeoffs (often under-discussed): GI tolerability Slowed motility nausea, bloating, constipation Muscle & lean mass considerations Weight loss isnt purely fat risk of lean mass loss without intervention Pancreatic biology Chronic -cell stimulation + remodeling dynamics still being studied System-wide modulation These are not targeted drugs, they actually alter multiple organ systems simultaneously Long-term unknowns Especially around chronic use in non-diabetic, younger populations Any we've missed here

This, combined with potential vomiting or diarrhea from GLP-1 agonists, can increase the risk of dehydration

The guidelines state, GLP-1 RAs may be considered for weight-loss in patients who have completed cancer therapy and may be considered with caution for patients on stable endocrine-based cancer therapies based on limited observational safety data. They also say, GLP-1 RAs cannot be recommended currently for patients receiving or initiating chemotherapies and/or immunotherapies due to lack of safety and outcomes data. Iyengar is director of Survivorship Services at Winship Cancer Institute of Emory University, a clinical member of Winships Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor-in-chief of the journal ONCOLOGY

Your initial consultation with our medical team is complimentary

However, in a secondary analysis, users of GLP-1 RA exhibited a significantly lower risk of hip fracture and a lower risk of MOF compared to DPP-4i users when allowing follow-up to continue after medication change

He said: Unlike cosmetic products, nasal tanning sprays are unlikely to have had expert safety assessment, and use of relevant health warnings and instructions for safe use are rare